Floatz logo

Docetaxel

Islet Cell Tumor

Eastern Cooperative Oncology GroupSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Islet Cell Tumor cohort.

Asset / SponsorPhaseRating
Irinotecan
M.D. Anderson Cancer Center
Phase 2/3BB
FLUOROURACILUM
H. Lee Moffitt Cancer Center and Research Institute
Phase 2/3BB
Calcium folinate pentahydrate
H. Lee Moffitt Cancer Center and Research Institute
Phase 2/3BB
PREDNISONE TABLETS
Exelixis
Phase 3BB
Octreotide Pamoate
RayzeBio, Inc.
Phase 3BB

View all 17 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →